Yves Allenbach
Allenbach, Yves, 1976-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 282814956 (Personal)
Permalink: http://viaf.org/viaf/282814956
Preferred Forms
-
100 1 _
‡a
Allenbach, Yves
‡d
1976-...
-
100 1 _
‡a
Allenbach, Yves,
‡d
1976-....
-
100 0 _
‡a
Yves Allenbach
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis |
|
| Activated dendritic cells modulate proliferation and differentiation of human myoblasts. |
|
| Analysis of cell surface and intranuclear markers on non-stimulated human PBMC using mass cytometry. |
|
| Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy |
|
| Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. |
|
| Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies |
|
| Antisynthetase Syndrome with Anti-Jo1 Antibodies in 48 Patients: Pulmonary Involvement Predicts Disease-modifying Antirheumatic Drug Use |
|
| Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis. |
|
| Autoantibodies at the Center of (sub)Classification-Issues of Detection-Reply |
|
| [Autoantibody profile in myositis]. |
|
| CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy |
|
| CD8+T-bet+ cells as a predominant biomarker for inclusion body myositis |
|
| Characterisation of autoreactives B cells in Sjögren's syndrome. |
|
| Comparison of MR T1 and T2 mapping parameters to characterize myocardial and skeletal muscle involvement in systemic idiopathic inflammatory myopathy (IIM) |
|
| Correction: Beneficial Role of Rapamycin in Experimental Autoimmune Myositis. |
|
| Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey' |
|
| Dermatomyosite à anticorps anti-Mi2 revisitée dermatomyosite pure avec nécrose et haut risque de malignité |
|
| Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis |
|
| Diagnostic Utility of Auto-Antibodies in Inflammatory Muscle Diseases. |
|
| Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases |
|
| Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis |
|
| Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis |
|
| Etude des cellules souches musculaires dans la dermatomyosite et les autres myosites. |
|
| EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors |
|
| Expanding the spectrum of livedoid vasculopathy: peculiar neuromuscular manifestations. |
|
| [Focal myositis: An unknown disease]. |
|
| Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: implications for therapeutic trials |
|
| Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositis |
|
| High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients |
|
| IFN-β-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis |
|
| The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis |
|
| Inclusion body myositis: accumulation of evidence for its autoimmune origin |
|
| Infliximab as effective treatment for aseptic neutrophilic myositis |
|
| Integrated classification of inflammatory myopathies |
|
| Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis |
|
| JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis |
|
| Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome |
|
| Médecine interne |
|
| Muscle Shear Wave Elastography in Inclusion Body Myositis: Feasibility, Reliability and Relationships with Muscle Impairments |
|
| Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology |
|
| Myogenic precursor cell impairment in dermatomyositis and other myositis |
|
| Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping. |
|
| Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. |
|
| Paraneoplastic dermatomyositis : role of anti-TIF1gamma antibodies and cancer in triggering dermatomyositis. |
|
| Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. |
|
| pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy |
|
| PD1 pathway in immune-mediated myopathies: Pathogenesis of dysfunctional T cells revisited |
|
| Peculiar clinicopathological features of immune-mediated necrotizing myopathies |
|
| A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. |
|
| Physical activity monitoring: A promising outcome measure in idiopathic inflammatory myopathies. |
|
| Proximal weakness in a patient with MALT lymphoma: a case report and discussion of possible pathogenesis. |
|
| Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis. |
|
| Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis |
|
| Reply: Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1. |
|
| Response to: 'On using machine learning algorithms to define clinically meaningful patient subgroups' by Pinal-Fernandez and Mammen |
|
| Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice |
|
| Rôle des anticorps monoclonaux au cours des myopathies auto-immunes : de l'étude des auto-anticorps spécifiques des myopathies nécrosantes auto-immunes à la description physiopathologique des myosites induites par l'immunothérapie anti-tumorale |
|
| Rôle des lymphocytes T régulateurs dans un nouveau modèle murin de myopathie inflammatoire et implications dans la physiopathologie et la thérapie de la Myosite à Inclusions |
|
| Sequestosome-1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies |
|
| Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation |
|
| Spectre clinique et pronostic des maladies auto-immunes associées aux anticorps anti PM-Scl |
|
| Study of the role of regulatory T cells in a new rodent model of auto-immune myositis and implication in patients with sporadic Inclusion Bosy myositis. |
|
| Synthesis and in vitro evaluation of tropane halogenated-derivatives against malaria, sleeping sickness, Chagas disease and leishmaniasis |
|
| Th1 response and systemic treg deficiency in inclusion body myositis. |
|
| Th2-M2 immunity in lesions of muscular sarcoidosis and macrophagic myofasciitis. |
|
| Tissue-specific and systemic analysis of inflammatory idiopathic myopathies and immune-checkpoint-inhibitor-induced myositis. |
|
| Usefulness of autoantibodies for the diagnosis of autoimmune myopathies |
|
| Value of magnetic resonance imaging for evaluating muscle inflammation: insights from a new mouse model of myositis |
|
